Glaukos

Q2 FY2026 EarningsQ2 FY26 results significantly exceeded consensus expectations, with revenue of $185.6M beating the $150.9M estimate by 23% and GAAP EPS of -$0.31 surpassing the -$0.289 mean. The primary driver was a 64% YoY surge in U.S. Glaucoma sales, fueled by the iDose TR launch. Management substantially raised FY26 revenue guidance to $680M-$700M, well above the prior $620M-$635M range and implied market expectations.